Insmed | INSM - Cost Of Sales


Insmed reported $49.5M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
BioMarin Pharmaceutical USD 199.48M 37.93M Mar/2026
Cytokinetics USD 160K 104.24M Mar/2026
Gilead Sciences USD 1.44B 174M Mar/2026
Heron Therapeutics USD 11.12M 795K Dec/2025
Insmed USD 49.5M 3.34M Mar/2026
Novartis USD 3.54B 7M Dec/2025
Regeneron Pharmaceuticals USD 669.4M 84.8M Mar/2026
Sarepta Therapeutics USD 109.46M 289.93M Mar/2026
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
Vertex Pharmaceuticals USD 392.8M 73.2M Mar/2026